XUAB2107-A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients with PD-L1+ Metastatic Triple Negative Breast Cancer (TARA)


Total Award Amount

  • 86185.00
  • Direct Costs

  • 63414.00
  • Sponsor Award Id

  • Contributor

  • Ahmed Elkhanany   Principal Investigator  
  • Drexell Boggs   Investigator  
  • Erica Stringer-Reasor M.D.   Investigator  
  • Gabrielle Rocque M.D.   Investigator  
  • Katia Khoury   Investigator